Johnson & Johnson’s Aticaprant Development Halt: A Blow to Kappa Opioid Therapies and Market Reactions March 8, 2025
Johnson & Johnson’s Aticaprant Setback Sends Shockwaves Through Depression Treatment Landscape March 8, 2025
Johnson & Johnson Halts Aticaprant Development, Casting Doubts on Kappa Opioid Receptor Drugs for Depression March 8, 2025
Johnson & Johnson Halts Promising Depression Drug Aticaprant Amid Efficacy Concerns, Shaking Biotech Sector March 8, 2025
Johnson & Johnson Halts Promising Depression Drug Aticaprant, Shaking Up Pharmaceutical Landscape March 7, 2025
UnitedHealth Paves the Way for Non-Opioid Pain Management with Coverage for Vertex’s Journavx March 7, 2025
Navigating Change: Dr. Martin Makary’s Path to Strengthening the FDA Amid Staffing Challenges March 6, 2025
Challenging the Status Quo: Dr. Martin Makary Faces Senate Scrutiny on FDA Vaccine Advisory Committee Changes March 6, 2025
Jazz Pharmaceuticals Strikes $935 Million Deal to Acquire Chimerix and Boost Oncology Pipeline with Promising Brain Cancer Treatment March 6, 2025
